Haemonetics Corp (NYSE: HAE) awards 2,538 restricted stock units to director

Rhea-AI Filing Summary

COYLE MICHAEL J reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Michael J. Coyle received an equity award of 2,538 restricted stock units (RSUs) tied to the company’s common stock on 2026-07-24 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one share of common stock when vested. Following this award, Coyle directly holds 17,932 shares of Haemonetics common stock.

Insider Trade Summary

Net Buyer: 2,538 shares

Net Buy 1 txn

Insider COYLE MICHAEL J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	2,538	--	--

Holdings After Transaction: Common Stock — 17,932 shares (Direct)

Footnotes (2)

1. F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
2. F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSUs awarded: 2,538 units Shares following transaction: 17,932 shares Vesting schedule: 100% after one year +1 more

4 metrics

RSUs awarded 2,538 units Equity award to director Michael J. Coyle on 2026-07-24

Shares following transaction 17,932 shares Total Haemonetics common shares directly owned by Michael J. Coyle after the award

Vesting schedule 100% after one year RSUs vest 100% on the first anniversary of the grant date

RSU to share ratio 1 RSU : 1 share Each RSU represents a contingent right to receive one share of common stock

Key Terms

restricted stock units, Amended and Restated 2019 Long-Term Incentive Compensation Plan, contingent right

3 terms

restricted stock units financial

"The securities awarded are in the form of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2019 Long-Term Incentive Compensation Plan financial

"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:54 PM Accepted by SEC EDGAR 07/28/2026 - 04:54 PM Learn about SEC filing dates

FAQ

What insider transaction did Haemonetics (HAE) report for Michael J. Coyle?

Michael J. Coyle received an award of 2,538 restricted stock units linked to Haemonetics common stock on 2026-07-24. The grant was issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan as part of his role as a director.

How many Haemonetics (HAE) shares does Michael J. Coyle hold after this RSU award?

After the reported award, Michael J. Coyle directly owns 17,932 shares of Haemonetics common stock. This figure reflects his total direct holdings immediately following the grant of 2,538 RSUs, as disclosed in the insider transaction report.

What are the vesting terms of Michael J. Coyle’s Haemonetics (HAE) RSUs?

The 2,538 RSUs awarded to Michael J. Coyle vest 100% on the first anniversary of the grant date. This means none of the units are vested initially; all become exercisable together one year after the 2026-07-24 grant.

What does each RSU granted to Michael J. Coyle at Haemonetics (HAE) represent?

Each RSU represents a contingent right to receive one share of Haemonetics common stock upon vesting. Once the RSUs vest, Coyle is entitled to receive an equivalent number of common shares, one share for each RSU awarded.

Is Michael J. Coyle’s Haemonetics (HAE) RSU grant tied to a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox for this insider report is not marked as affirmative, indicating the transaction is not represented as executed under a Rule 10b5-1 trading plan. The award instead reflects a structured equity grant under the company’s incentive plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COYLE MICHAEL J

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		A		2,538(1)	A	(2)	17,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Coyle	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)